StockNews.AI
HTZ
StockNews.AI
116 days

Elixir Medical Announces First Use of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Asia Pacific at Cardiac Vascular Sentral Kuala Lumpur (CVSKL), Malaysia

1. Elixir Medical launched LithiX™ HC-IVL technology in Asia for calcified lesions. 2. First clinical use demonstrated at TCTAP Congress with encouraging outcomes. 3. New system minimizes vessel trauma and does not need external energy. 4. High prevalence of calcified lesions indicates strong market potential in Asia. 5. Elixir Medical recognized as one of the world's most innovative companies.

5m saved
Insight
Article

FAQ

Why Neutral?

While the technology is innovative, its unavailability in the U.S. limits immediate commercial impact on HTZ. Historical innovations in the medical field have led to varied investor reactions, often tinged with caution until revenue impacts are visible.

How important is it?

The unveiling of a new technology may indirectly influence investor interest, but its immediate effect on HTZ's stock price is limited due to market focus; innovations in medical devices resonate more closely with sector-specific stocks.

Why Long Term?

The technology's adoption may positively influence Elixir Medical's market position over time but does not give HTZ immediate leverage. Historical patterns show industry shifts take several years to reflect in stocks, especially in sectors tied to medical innovation.

Related Companies

ELMDABTMDT
First cases completed by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD, and transmitted live at TCTAP Congress in Seoul, Korea. Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an external energy source. MILPITAS, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the first clinical use of its LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in the Asia Pacific region, marking a significant milestone in the device's global introduction. The procedures were successfully performed at Cardiac Vascular Sentral Kuala Lumpur Hospital in Kuala Lumpur by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD. The LithiX™ HC-IVL device represents a novel mechanical approach to calcium modification in calcified coronary lesions, offering the benefits of intravascular lithotripsy using prior technologies without requiring an external energy source. Based on the Hertz Contact Stress principle, the device delivers precise mechanical amplification of force to achieve calcium fractures while minimizing unintended vessel trauma. “The ability to safely perform complex PCI and treat severe calcium with a mechanical IVL system like LithiX™ is a significant advancement for our practice and a big win for patients in our region,” said Dr. Tamil Selvan Muthusamy, MD. “We’re proud to be the first center in Asia to adopt this innovative technology and demonstrate the excellent clinical outcomes via a live case transmission at TCTAP congress.” The LithiX™ HC-IVL System features low-profile metal hemispheres integrated on a semi-compliant balloon. When inflated at low pressure, via the Hertz Contact Stress principle, these hemispheres amplify force at contact points with calcium to produce deep and wide fractures, effectively modifying complex calcified lesions while minimizing injury to healthy vessel tissue. “Prevalence of calcified lesions is very high in Asia Pacific, and the interventional cardiology community has long been waiting for a more optimal IVL solution to treat our patients. With LithiX™, we now have a simple-to-use and versatile lithotripsy solution that demonstrated excellent results in our very complex cases,” said Dr. Rosli Mohd Ali, MD. Motasim Sirhan, CEO of Elixir Medical, stated, “With LithiX™, we’ve developed the first mechanical IVL platform capable of fracturing calcium without requiring an external energy source while avoiding injury to adjacent healthy vessel. The expansion into Malaysia and the greater Asia Pacific region demonstrates global recognition of its unique performance and procedural advantages.” ​​About Elixir Medical Elixir Medical Corporation, a privately held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheral artery disease. Our transformative technologies have multiple applications across the cardiovascular space capable of delivering improved clinical outcomes for millions of patients. Elixir Medical was named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. Visit us at www.elixirmedical.com and on LinkedIn and X. The LithiX™ HC-IVL system is CE Mark approved. Not available for sale in the United States.

Related News